Arrakis bolsters RNA-targeting tech with UPenn license

Arrakis CEO Michael Gilman.

Arrakis Therapeutics has licensed technology from the University of Pennsylvania that enables the targeting of RNA with small molecules. The deal gives Arrakis rights to families of compounds that bind to three-way junctions found in folded RNA.

Waltham, Massachusetts-based Arrakis emerged earlier this year with a $38 million A round and plans to search for small molecules that bind RNA. That focus puts Arrakis into largely virgin drug discovery territory with huge potential. But to realize that potential it must go after macromolecules previously dismissed as undruggable.

The University of Pennsylvania agreement gives Arrakis another tool to apply to that tough task. 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

David Chenoweth, Ph.D., a University of Pennsylvania associate professor and scientific advisor to Arrakis, is behind the IP picked up by the startup. Chenoweth’s work centers on molecules that bind to three-way junctions, nucleic acid structures found in folded RNA. 

Research into these structures dates back more than a decade. But efforts to create small molecule platforms capable of targeting the structures are only just starting to bear meaningful fruit. 

“The lifecycle of RNA is very complex and we are just beginning to understand and predict the different structural components that impact the production of proteins from mRNA,” Chenoweth said. “Our team has just begun to elucidate the role of three-way junctions and how they may open a new avenue for the discovery of small molecules that bind to RNA and intervene in disease processes.”

Chenoweth’s work will slot in alongside Arrakis’ own attempts to drug RNA. The biotech has been plugging away on the idea since 2015 in a belief that ever-expanding knowledge of the structure of RNA, specifically its loops and pockets, is creating opportunities to drug the macromolecule.

If Arrakis succeeds, a vista of therapeutic opportunities will open up. 

Suggested Articles

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.